Researchers from Curta and the University of Washington partnered on a manuscript comparing how the Institute of Clinical and Economic Review (ICER) value-based prices compare to list prices of recently approved drugs. The report covers 95 drugs evaluated by ICER across 35 indications. ICER highlighted the manuscript in their weekly newsletter and responded on social media, noting the opportunity for fair pricing of drugs based on alignment with ICER’s recommendations.
To access the full publication, visit https://www.sciencedirect.com/science/article/pii/S1098301521001066